New Study Tests Hypothesis That Disruption Of Estrogen
Receptor-Α Leads To Decreased Nitric Oxide-Dependent Vasodilation In
Coronary Arteries
November 10, 2003 - (Bethesda, MD) – In women,
the risk of coronary heart disease increases significantly after menopause.
Estrogen therapy, however, reduces the risk of cardiovascular disease in
healthy postmenopausal women. Estrogen enhances endothelial function of the
coronary arteries, and this may contribute to the cardioprotective effects
of the female hormone.
The precise mechanisms that mediate the beneficial
effects of estrogen on arterial endothelial function are incompletely
understood. What is known is that the long-term effects of estrogen occur
through activation of estrogen receptors and subsequent modulation of gene
expression. Moreover, estrogen has also been shown to effect
endothelium-dependent function via its effects on expression of endothelial
nitric oxide synthase.
A New Study
Accordingly, a new study tests the hypothesis that
estrogen modulates nitric oxide (NO)-dependent vasodilation of coronary
arteries through its action on estrogen receptor-α (ER-α) to increase
protein levels of endothelial nitric oxide synthase (eNOS) and Cu/Zn
superoxide dismutase (SOD-1). The authors of the study, entitled “Regulation
of Nitric Oxide-Dependent Vasodilatation in Coronary Arteries of Estrogen
Receptor-α-Deficient Mice,” are Judy M. Muller-Delp, Kathryn E. Nichol,
Texas A&M University, College Station, TX; and Dennis B. Lubahn, Brian J.
Philips, Elmer M. Price, Edward M. Curran and M. Harold Laughlin, all of the
University of Missouri, Columbia, MO. Their findings appear in the November
2003 edition of the American Journal of Physiology—Heart and Circulatory
Physiology, one of 14 journals published each month by the American
Physiological Society (APS).
Methodology
The investigators followed the primary procedures
outlined below:
Animals: A total of
43 ERα knockout (ERαKO) mice and 36 wild-type (WT)
female mice were used for the study of coronary artery vasomotor reactivity
experiments. A total of 19 ERαKO and 18 WT females were used for
immunoblot experiments. The average age of ERαKO mice was 16 +
1 wk. In WT mice, the average age was 15 + 1 wk. Within the WT group,
16 mice were ovariectomized. Sixteen ERαKO mice were
ovariectomized. Experiments were performed beginning 10 days or more after
ovariectomy. Estrogen treatment was initiated after 10 days of rest
following the procedure. Seventeen of the ovariectomized ERαKO
and eight of the ovariectomized WT mice received subcutaneous implants of a
17β-estradiol (E2) pellet; E2 treatment was continued for 14 days before the
mice died and the coronary arteries were harvested.
Isolation of coronary
arteries: The hearts were excised and placed in cold saline solution.
With the use of a dissecting microscope, coronary arteries were dissected
free of surrounding myocardium and cannulated. Arteries that exhibited leaks
were discarded and the remainder pressurized. Spontaneous tone was ensured
between the WT and ERαKO mice.
Evaluation of eNOS and
SOD-1 protein: Coronary arteries were isolated from the myocardium, as
noted above, and frozen in microcentrifuge tubes. Because there was
insufficient protein in a single mouse coronary artery to allow measurement
of protein content and still have sufficient sample to run on an SDS gel, it
was necessary to pool samples of coronary arteries from three mice into one
sample. The eNOS and SOD-1 protein content was determined by loading equal
amounts of total artery protein from equal numbers of different groups on
the same gel, allowing comparisons between groups on the same gel.
Solutions and drugs: Stock solutions of albumin and endothelin were
used.
Data analysis: Tone
development was expressed as the percent decrease from maximal diameter
according to the formula: Tone (%) = [(Dm – D8)/Dm]
x 100, where Dm is the maximal diameter recorded at 60 cmH2O
and Ds is the steady-state diameter recorded after
equilibration of the vessel. Vasodilatory responses were recorded as actual
diameters and subsequently expressed as the percent of maximal relaxation,
according to the formula Relaxation (%) = [(D8 – Db)/Dm
– Db)] x 100, where Ds is recorded after
each addition of the drug and Db is the initial baseline
diameter recorded immediately before the first addition of the vasodilatory
agent. A two-way repeated-measures ANOVA was used to detect differences
between and within factors. Statistical significance was defined as P
< 0.05.
Results
The primary findings of this study reveal that:
-
NO-mediated vasodilation was preserved in coronary arteries
from ERαKO mice;
-
SOD-1 protein content increased in coronary arteries from ERαKO
mice;
-
ovariectomy reduced NO-mediated vasodilation and protein
levels for eNOS and SOD-1 in ERαKO mice; and
-
E2 supplementation restored NO-mediated vasodilation and
protein content of eNOS and SOD-1 in ovariectomized ERαKO mice.
Conclusions and Discussion
Based on the above findings, the researchers conclude
that NO-mediated dilation is preserved in ERαKO mice through
compensatory activation of ER-α independent pathways. Further
study is needed to determine whether modulation of endothelium-dependent,
NO-mediated vasodilation in coronary arteries occurs through an ER-β
pathway.
-end-
Source: November 2003 edition of the American
Journal of Physiology—Heart and Circulatory Physiology.
The American Physiological Society (APS)
was founded in 1887 to foster basic and applied science, much of it relating
to human health. The Bethesda, MD-based Society has more than 10,000 members
and publishes 3,800 articles in its 14 peer-reviewed journals every year.
***
Editor’s Note: A copy of the research article is
available in pdf format to the press. Members of the press are invited to
obtain a pdf copy of the study and to interview members of the research
team. To do so, please contact Donna Krupa at 703.527.7357 (direct dial),
703.967.2751 (cell) or djkrupa1@aol.com.